Travere Therapeutics (TVTX) Gross Margin (2014 - 2026)

Travere Therapeutics' Gross Margin history runs 13 years deep, the most recent figure standing at 98.47% for Q1 2026.

• Quarterly Gross Margin rose 419.0% year-over-year to 98.47% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 110.86% (up 1485.0% YoY) and the FY2025 annual result came in at 11.17%, down 10785.0% from the prior year.
• Gross Margin was 98.47% for Q1 2026 at Travere Therapeutics, down from 100.73% in the prior quarter.
• Across five years, Gross Margin topped out at 100.73% in Q4 2025 and bottomed at 86.58% in Q1 2023.
• A 5-year average of 95.29% and a median of 96.19% in 2024 frame the typical range for Gross Margin.
• Annual changes were most pronounced in 2023 — Gross Margin tumbled 717 bps — and 2024, when it soared 978 bps.
• Travere Therapeutics' Gross Margin stood at 97.04% in 2022, then decreased by 7 bps to 89.87% in 2023, then climbed by 7 bps to 96.59% in 2024, then gained by 4 bps to 100.73% in 2025, then fell by 2 bps to 98.47% in 2026.
• Business Quant data shows TVTX's Gross Margin at 98.47% in Q1 2026, 100.73% in Q4 2025, and 96.04% in Q3 2025.